CN Patent

CN113620933A — Rho激酶抑制剂

Assigned to Kadmon Corp LLC · Expires 2021-11-09 · 5y expired

What this patent protects

本发明涉及Rho激酶抑制剂。本发明涉及ROCK1和/或ROCK2的抑制剂。还提供了治疗疾病或病症的方法，所述方法包括抑制ROCK1和/或ROCK2。

USPTO Abstract

本发明涉及Rho激酶抑制剂。本发明涉及ROCK1和/或ROCK2的抑制剂。还提供了治疗疾病或病症的方法，所述方法包括抑制ROCK1和/或ROCK2。

Drugs covered by this patent

belumosudil-mesylate (BELUMOSUDIL MESYLATE)

Patent Metadata

Patent number: CN113620933A
Jurisdiction: CN
Classification: —
Expires: 2021-11-09
Drug substance claim: No
Drug product claim: No
Assignee: Kadmon Corp LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.